Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody.

Abstract

We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who showed high titers of anti-sulfated glucuronyl paragloboside (SGPG) IgM antibody without M-protein in serum. The patient was resistant to corticosteroids and immunosuppressants, but after administration of rituximab, clinical symptoms improved and the patient remained in a stable state for approximately 10 months. Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine.

• Authors: Takahisa Gono, Masayuki Matsuda, Yasuhiro Shimojima, Wataru Ishii, Kanji Yamamoto, Hiroshi Morita, Takao Hashimoto, Keiichiro Susuki, Nobuhiro Yuki, Shu-ichi Ikeda
• Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (J Clin Neurosci) Vol. 13 Issue 6 Pg. 683-7 (Jul 2006) ISSN: 0967-5868 [Print] Scotland
• PMID: 16814550 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antirheumatic Agents
• Globosides
• Immunoglobulin M
• sulfate-3-glucuronyl paragloboside
• Rituximab

Topics

• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antirheumatic Agents (therapeutic use)
• Drug Therapy, Combination
• Follow-Up Studies
• Globosides (immunology)
• Humans
• Immunoglobulin M (therapeutic use)
• Male
• Neural Conduction (drug effects, physiology, radiation effects)
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (drug therapy, physiopathology)
• Reaction Time (drug effects, radiation effects)
• Rituximab